A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms VESSU
- 12 May 2011 Actual end date (May 2011 added as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.